ArticleInternational journal of molecular sciences2012
A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum.
Article in International journal of molecular sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Utility of CA-125 for diagnosis and prognosis of breast cancer: a systematic review.Exploration of targeted anti-tumor therapy · 2025Pooled it
- Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.British journal of cancer · 2017Trial
- Exploring potent miRNA combinations for detecting early-stage breast cancer.Molecular therapy. Nucleic acids · 2025Article
- Use of latex microbeads for detection of Plasmodium vivax lactate dehydrogenase using flow cytometry.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Article
- Serum Direct Bilirubin as a Biomarker for Breast Cancer.Breast cancer (Dove Medical Press) · 2024Article
- Diagnostic applications of microsphere-based flow cytometry: A review.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer.Translational oncology · 2022Article
- Identification and validation of plasma biomarkers for diagnosis of breast cancer in South Asian women.Scientific reports · 2022Article
- Improving breast cancer prediction using a pattern recognition network with optimal feature subsets.Croatian medical journal · 2021Article
- Prediagnostic circulating metabolites in female breast cancer cases with low and high mammographic breast density.Scientific reports · 2021Article
- Article
- Review
- Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer.Cancers · 2020Review
- Plasma extracellular vesicle‑packaged microRNAs as candidate diagnostic biomarkers for early‑stage breast cancer.Molecular medicine reports · 2019Article
- Article
- Prognostic Values Of Preoperative Serum CEA And CA125 Levels And Nomograms For Young Breast Cancer Patients.OncoTargets and therapy · 2019Article
- Early diagnosis of disease using microbead array technology: A review.Analytica chimica acta · 2018Review
- Article
- Assessing biological and technological variability in protein levels measured in pre-diagnostic plasma samples of women with breast cancer.Biomarker research · 2017Article
- Macrophage migration inhibitory factor involvement in breast cancer (Review).International journal of oncology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates whether a set of ten potential breast cancer serum biomarkers and cancer antigens (osteopontin (OPN), haptoglobin, cancer antigen 15-3 (CA15-3), carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125), prolactin, cancer antigen 19-9 (CA19-9), α-fetoprotein (AFP), leptin and migration inhibitory factor (MIF)) can predict early stage breast cancer in samples collected before clinical diagnosis (phase III samples). We performed a nested case-control study within the Prospect-EPIC (European Prospective Investigation into Cancer and nutrition) cohort. We examined to what extent the biomarker panel could discriminate between 68 women diagnosed with breast cancer up to three years after enrollment and 68 matched healthy controls (all 56-64 years at baseline). Using a quantitative bead-based multiplexed assay, we determined protein concentrations in serum samples collected at enrollment. Principal Component Analysis (PCA) and Random Forest (RF) analysis revealed that on the basis of all ten proteins, early cases could not be separated from controls. When we combined serum protein concentrations and subject characteristics related to breast cancer risk in the RF analysis, this did not result in classification accuracy scores that could correctly classify the samples (sensitivity: 50%, specificity: 50%). Our findings indicate that this panel of selected tumor markers cannot be used for diagnosis of early breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.